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Abstract
Stimulation of monocytes with microbial and non-microbial products, including oxidized low-density lipoprotein (oxLDL), induces
a protracted pro-inflammatory, atherogenic phenotype sustained by metabolic and epigenetic reprogramming via a process called
trained immunity. We investigated the intracellular metabolic mechanisms driving oxLDL-induced trained immunity in human
primary monocytes and observed concomitant upregulation of glycolytic activity and oxygen consumption. In two separate cohorts
of healthy volunteers, we assessed the impact of genetic variation in glycolytic genes on the training capacity of monocytes and
found that variants mapped to glycolytic enzymes PFKFB3 and PFKP influenced trained immunity by oxLDL. Subsequent
functional validation with inhibitors of glycolytic metabolism revealed dose-dependent inhibition of trained immunity in vitro.
Furthermore, in vivo administration of the glucose metabolism modulator metformin abrogated the ability for human monocytes to
mount a trained response to oxLDL. These findings underscore the importance of cellular metabolism for oxLDL-induced trained
immunity and highlight potential immunomodulatory strategies for clinical management of atherosclerosis.
Key messages
& Brief stimulation of monocytes to oxLDL induces a prolonged inflammatory phenotype.
& This is due to upregulation of glycolytic metabolism.
& Genetic variation in glycolytic genes modulates oxLDL-induced trained immunity.
& Pharmacological inhibition of glycolysis prevents trained immunity.
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Introduction
Atherosclerosis is characterized by chronic low-grade
inflammation of the arterial wall and monocyte-derived
macrophages are the most abundant cells in atheroscle-
rotic plaques [1]. We recently established that mono-
cytes and macrophages can build a long-term pro-in-
flammatory memory following brief exposure to micro-
bial products (e.g., Bacille Calmette-Guérin (BCG), and
the fungal cell wall component β-glucan), by a process
called trained immunity [2, 3]. Importantly, trained im-
munity is also induced by sterile, endogenous com-
pounds known to contribute to atherosclerosis, such as
oxidized low-density lipoprotein (oxLDL), lipoprotein
(a), and aldosterone [4–6]. Cells trained with oxLDL
are characterized by an increased cytokine production
capacity and enhanced foam cell formation [4].
Therefore, while trained immunity is beneficial in the
context of host defense against micro-organisms, it
may play a maladaptive role in chronic inflammatory
diseases [7]. To this end, we recently hypothesized that
trained immunity contributes to the persistent inflamma-
tion in atherosclerosis [8, 9]. Indeed, circulating mono-
cytes isolated from patients with established atheroscle-
rosis or patients with hypercholesterolemia exhibit a
trained phenotype [10, 11].
Trained immunity induced by β-glucan or BCG is associ-
ated with profound intracellular metabolic reprogramming,
characterized by increased glycolyticmetabolism and intracel-
lular accumulation of fumarate and mevalonate [2, 12–14]. β-
Glucan training is furthermore accompanied by the repression
of oxidative phosphorylation (OXPHOS), reminiscent of
Warburg metabolism, whereas BCG-induced trained immuni-
ty is supported by concomitant increases in glycolysis and
OXPHOS [15].
At the level of gene regulation, trained immunity is char-
acterized by epigenetic changes that modulate transcription-
al programs. Studies of cells trained with β-glucan [16] and
BCG [15] have associated the enrichment of H3 histones
trimethylated at lysine 4 (H3K4me3) at regulatory pro-
moters with increased expression of genes involved in gly-
colytic metabolism, thus linking immunometabolic and epi-
genetic reprogramming. On the other hand, there is evi-
dence of a reverse-causal relationship, whereby blocking
the activation of aerobic glycolysis precludes the character-
istic chromatin modification pattern and adapted phenotype
of trained immunity [16].
The current study is aimed at unraveling the role of meta-
bolic reprogramming in oxLDL-induced trained immunity.
Materials and methods
Cells and reagents
Buffy coats from healthy donors were obtained after written
informed consent (Sanquin Blood Bank, Nijmegen, the
Netherlands). Human peripheral blood mononuclear cells
(PBMCs) were isolated by density-gradient centrifugation over
Ficoll-Paque (GE Healthcare). Percoll isolation of monocytes
was performed as previously described as yielding a level of T
cell contamination, measured by fluorescence-activated cell
sorting of only 5% [13, 17]. Purified monocytes were cultured
in RPMI 1640 Dutch-modified culture medium (RPMI medi-
um, Invitrogen) supplemented with 50 μg/mL gentamicin
(Centraform), 2 mmol/L Glutamax (Invitrogen), 1 mmol/L py-
ruvate (Invitrogen), and 10% pooled human serum. Stimuli and
inhibitors used were Escherichia coli lipopolysaccharide (LPS;
serotype 055:B5, Sigma-Aldrich, 10 ng/mL), Pam3Cys (EMC
Microcollections, L2000, 10 μg/mL), 3-(3-pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one (3PO, Sigma-Aldrich), and 2-de-
oxy-D-glucose (2-DG, Sigma-Aldrich). Low-density lipopro-
tein was isolated from pooled human serum by ultracentrifuga-
tion and oxidized by incubating with 20 μmol CuSO4/L for
16 h at 37 °C followed by dialysis, as previously described [4].
In vitro training and pharmacological inhibition
Adherent monocytes were trained as described previously
[17]. Briefly, cells were incubated with oxLDL (10 μg/mL)
for 24 h, washed with phosphate-buffered saline (PBS), and
incubated in normal culture medium at 37 °C, 5% CO2. For
pharmacological inhibition experiments, cells were co-
incubated with inhibitors (3PO [10–40 μmol/L], 2-DG
[1 mmol/L], metformin [10 μmol/L]) for the 24 h of oxLDL
stimulation. For glucose experiments, cells were incubated
with oxLDL (10 μg/mL) in culture medium supplemented
with 5 mM glucose (+ 20 mM mannitol) or 25 mM glucose
for 24 h, washed with warm PBS, and incubated with RPMI
supplemented with 6 mM glucose and 10% pooled human
serum (obtained anonymously from the laboratory of our hos-
pital) at 37 °C, 5% CO2. Following 5 days in culture, cells
were restimulated with medium alone, 10 ng/mL LPS.
Cytokine measurement
Cytokine production in supernatants after 24 h or 7 days was
determined using commercial enzyme-linked immunosorbent
assay kits for TNF-α and IL-6 (R&D Systems, MN, USA)
according to the instructions of the manufacturers.
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Quantitative RT-PCR
Total RNA was isolated from macrophages using TRIzol re-
agent according to the manufacturer’s instructions. 0.5–1 μg
of total RNA was used to synthesize cDNA with the
SuperScript III First-Strand Synthesis System (Thermo
Fisher Scientific) according to the manufacturer’s protocol.
Quantitative RT-PCR was performed using an Applied
Biosciences StepOnePLUS qRT-PCR machine using SYBR
Green (Invitrogen). All reactions were performed for at least 6
biological replicates and the values expressed as log2 fold
increase in mRNA levels relative to those in non-trained cells.
18s was used as a housekeeping gene. RT-PCR primers are
listed in Table S1.
Chromatin immunoprecipitation
Trained monocytes on day 6 were cross-linked in methanol-
free 1% formaldehyde, followed by sonication and immuno-
precipitation using antibodies against H3K4me3 (Diagenode,
Seraing, Belgium). Immunoprecipitated chromatin was proc-
essed further for qRT-PCR analysis using the MinElute DNA
Purification Kit (Qiagen). Primers used in the reaction are
listed in Table S1. Samples were analyzed with a comparative
Ct method on the StepOnePLUS qPCR machine (Applied
Biosystems) using SYBR green (Invitrogen) in accordance
with the manufacturer’s instructions.
Metabolic analysis
Approximately 1 × 107 monocytes were trained with oxLDL
(10 μg/mL) in 10-cm Petri dishes (Greiner) in 10 mL medium
volumes for 24 h, washed with warm PBS, and incubated in
normal culture medium at 37 °C, 5% CO2. Following 5 days
in culture, cells were detached with Versene solution (Thermo
Fisher Scientific) and 1 × 105 cells were plated in quintupli-
cate to overnight-calibrated cartridges in assay medium
(RPMI with 0.6 mmol/L glutamine, 5 mmol/L glucose, and
1 mmol/L pyruvate [pH adjusted to 7.4]) and incubated for 1 h
in a non-CO2-corrected incubator at 37 °C. Trained and un-
trained macrophages for each respective donor were included
in the same assay. Oxygen consumption rate (OCR) and ex-
tracellular acidification rate (ECAR) were measured using a
Cell Mito Stress Kit (for OCR) or a glycolysis stress test (for
ECAR) kit in an XFp Analyzer (Seahorse Bioscience), with
final concentrations of 1μmol/L oligomycin, 1μmol/L FCCP,
and 0.5 μmol/L rotenone/antimycin A.
Genetic analysis
We conducted in vitro oxLDL training of adherent PBMCs
from 119 healthy individuals of Western European ancestry
from the 200 Functional Genomics cohort (2011/399) of the
Human Fun c t i o n a l G e n om i c s P r o j e c t (www.
humanfunctionalgenomics.org). Genotype information on
approximately 8 million single-nucleotide polymorphisms
( S N P s ) w a s o b t a i n e d u s i n g I l l u m i n a
HumanOmniExpressExome SNP chip upon imputation.
Only SNPs with a minor allele frequency of ≥ 5% that passed
standard quality filters were included in the analysis. Raw
cytokine levels were log-transformed and the ratio between
trained and non-trained cytokine levels was used to quantify
the trained immunity response. They were subsequently
mapped to genotype data using a linear regression model with
age and gender as covariates [18].
We also conducted in vitro oxLDL training of adherent
PBMCs in a second cohort of 243 healthy individuals of
Western European ancestry from the 300BCG cohort
(NL58553.091.16). DNA samples of the individuals from
the second cohort were genotyped using the commercially
available SNP chip, Infinium Global Screening Array MD
v1.0 from Illumina. Genotype information on approximately
4 million SNPs was obtained upon imputation (MAF > 5%
and R2 > 0.3 for imputation quality).
After removing genetic outliers, cytokine ratios were
mapped to genotype data as described for the 200FG cohort.
Ethical approval of the cohort studies was granted by the
local Ethics Committee (CMO regio Arnhem-Nijmegen;
numbers 2011/399 and NL58553.091.16). Inclusion of volun-
teers and experiments were conducted according to the prin-
ciples expressed in the Declaration of Helsinki. All volunteers
gave written informed consent before any material was taken.
Metformin trial
In this prospective study, 11 healthy non-obese volunteers
received increasing doses of metformin for a total of 6 days
(starting at 500 mg once per day and ending with 1000 mg
twice per day). Baseline characteristics of the participants are
described in Table S2. Blood was drawn immediately before
metformin administration (day 0), immediately after adminis-
tration (day 6), as well as 3 days (day 9) and 2 weeks (day 20)
after the final dose. The study was approved by the local
institutional review committee (Arnhem-Nijmegen Medical
Ethical Committee, NL47793.091.14) and conducted accord-
ing to the principles of the International Conference on
Harmonization-Good Clinical Practice guidelines. All volun-
teers gave written informed consent before participation.
Statistical analysis
Ex vivo and in vitro monocyte experiments were analyzed
using a Wilcoxon signed-rank test. R-package Matrix eQTL
was used for cytokine QTLmapping. A p value < 0.05 (*) was
considered statistically significant, (**) p < 0.01. Data repre-
sent mean ± SEM.
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Results
oxLDL-induced trained immunity is associated
with increased glycolytic metabolism and oxygen
consumption
To investigate the metabolic phenotype of monocytes trained
with oxLDL, we incubated human primary monocytes with
culture medium or oxLDL (10 μg/mL) for 24 h. On day 6, the
cells were restimulated with culture medium alone or the Toll-
like receptor 4 ligand lipopolysaccharide (LPS, 10 ng/mL) for
24 h, after which pro-inflammatory cytokine production was
measured (Fig. 1a). Tumor necrosis factor alpha (TNF-α) and
interleukin 6 (IL-6) were measured as numerous studies of
trained immunity demonstrate that these cytokines are reliable
functional readouts for pro-inflammatory cytokine production
in trained cells [13, 16]. In accordance with previous findings
[4], we observed that cells that had been stimulated with
oxLDL exhibited enhanced TNF-α and IL-6 production fol-
lowing LPS restimulation (Fig. 1b).
To understand the mechanisms supporting this phenotype,
we analyzed the metabolism of trained cells using Seahorse
XF technology. Five days after removal of the oxLDL from
the culture medium, trained macrophages were distinguish-
able by an increased rate of extracellular acidification
(ECAR) (Fig. 1c), signifying enhanced glycolytic flux. In ad-
dition, the rate of oxygen consumption (OCR) was increased
in cells trained with oxLDL (Fig. 1d), indicating concurrent
upregulation of OXPHOS. Previous studies have reported
transcriptional activation of genes related to glycolysis in
trained immunity [10, 15, 16]. To determine if this was also
true for macrophages trained with oxLDL, we analyzed the
mRNA expression of key glycolytic enzymes. Following 4 h
of LPS restimulation (Fig. 1a), we observed a trend toward
upregulation of genes encoding glycolytic pathway enzymes
PFKP, PKM1, and PKM2 in cells incubated with RPMI.
Statistically significant differences were observed for HK2
and PFKFB3 in untrained macrophages stimulated with
LPS. Training with oxLDL exacerbated this effect, par-
ticularly for PFKFB3 mRNA expression. In contrast, the
expression of genes encoding pyruvate kinase enzymes
PKM1 and PKM2 was not significantly altered by
oxLDL training (Fig. 1e).
Genetic variation in glycolytic enzymes determine
the individual susceptibility to oxLDL-induced
training
To further understand the role of the metabolic adaptations, we
investigated if genetic variation affects individual susceptibil-
ity for trained immunity using a genetic study of 119 healthy
volunteers. PBMCs were incubated with culture medium or
10 μg/mL oxLDL for 24 h. Cells were washed and incubated
in normal culture conditions for a further 5 days. On day 6, the
cells were restimulated with culture medium alone or LPS
(10 ng/mL) for 24 h. We confirmed that the oxLDL-
dependent augmented production of TNF-α and IL-6 previ-
ously seen in enriched monocyte fractions was also detectable
in PBMCs (Fig. 2a). Furthermore, we observed considerable
inter-individual variation in cytokine production by oxLDL-
trained cells (Fig. 2b). To investigate the sources of this
variation, we explored the potential influence of factors
known to affect cytokine production and observed no effect
of age (Fig. 2c) or sex (Fig. 2d).
To understand the impact of genetic variation on cytokine
production, we tested for associations among SNPs and the
magnitude of oxLDL-trained cytokine responses of individual
subjects. Genome-wide significant (p < 5 × 10−8) QTLs were
not observed. However, to increase sensitivity, we studied all
SNPs with a p value < 9.99 × 10−3 Using this approach, we
identified several SNPs suggestively associated with adaptive
changes in cytokine production mapped within 250 kB of
genes encoding key glycolytic enzymes. Specifically, genetic
variation in genes encoding the inducible PFK-2/FBPase iso-
zyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
(PFKFB3) and phosphofructokinase (PFKP) were associated
with the potentiation of TNF-α and IL-6 production upon
training with oxLDL (Fig. 3a). With regard to TNF-α produc-
tion by oxLDL-trained cells, the most strongly associated SNP
was rs9423713 (p = 7.5 × 10−5) which is located within an
enhancer region approximately 100 kB downstream of
PFKP (GeneHancer ID: GH10J003171). For IL-6 production,
the SNP most strongly associated with oxLDL training was
rs4747882 (PFKFB3, p = 5.69 × 10−5) (Fig. 3b). We validated
these findings using an independent genetic study of 243
healthy volunteers. Testing for associations among common
SNPs (MAF > 5%) and variation in the magnitude of oxLDL-
trained cytokine responses across this cohort, we identified
several SNPs suggestively associated with adaptive changes
in cytokine production mapped within 250 kB of genes asso-
ciated with glycolysis (p < 9.99 × 10−3) (Fig. 3c). Like the first
cohort, some of the strongest associations were observed for
Fig. 1 Induction of trained immunity by oxidized low-density lipoprotein
is dependent on glycolytic metabolism. a Graphical outline of in vitro
training methods. b Human primary monocytes were incubated for 24 h
with culture medium (RPMI, open bars) or oxLDL (closed bars), allowed
to rest for 5 days and then stimulated for 24 h with LPS (10 ng/mL), and
levels of IL-6 and TNF-α were assessed in supernatants by enzyme-
linked immunosorbent assay (mean ± SEM, n = 8, **p < 0.01,
Wilcoxon signed-rank test). c Extracellular acidification rate (ECAR)
and d oxygen consumption rate (OCR) of cells incubated with RPMI or
trained with oxLDL determined by Seahorse XF technology at day 6
(prior to restimulation) (mean ± SEM, n = 7, *p < 0.05, Wilcoxon
signed-rank test). e mRNA expression of genes encoding enzymes in-
volved in glycolysis measured by qRT-PCR 4 h after restimulation with
LPS (mean ± SEM, n = 6)
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variants mapped to genes encoding PFKP and PFKFB3. The
SNPs most strongly associated to TNF-α production were
rs9423688 (intron 16 of PFKP, p = 0.002) and rs55643411
(exon 15 of PFKFB3, p = 0.001), whereas SNPs strongly as-
sociated with IL-6 production included rs10762282 (intron 4
of HK1, p = 0.0004) and rs55643411 (PFKFB3, p = 0.001)
(Fig. 3d). Together, these data suggest that glycolysis is a
key metabolic pathway for pro-inflammatory cytokine pro-
duction in trained immunity induced by oxLDL.
Pharmacological inhibition of glycolysis prevents
oxLDL-induced trained immunity
To determine the physiological significance of changes in gly-
colytic metabolism, we used two distinct approaches to
pharmacologically target glycolysis. First, we inhibited
PFKFB3, a crucial rate-limiting enzyme in glycolysis, which
is upregulated in oxLDL-trained cells [19]. Co-incubation of
3PO with oxLDL for the first 24 h of the in vitro training
protocol dose-dependently attenuated the oxLDL-augmented
production of TNF-α (Fig. 4a) and IL-6 (Fig. 4b) upon second-
ary stimulation with LPS. The dependency of oxLDL-mediated
trained immunity on glycolytic metabolism was further validat-
ed using the direct inhibitor of glycolysis 2-DG, which also
blunted the enhanced cytokine production (Fig. 4c and d).
Epigenetic enrichment of transcriptionally permissive
H3K4me3 was previously described at the promoters of genes
encoding pro-inflammatory cytokines in macrophages trained
with oxLDL [4], BCG [15], and β-glucan [16]. We were
therefore prompted to investigate the connection between
Fig. 2 Inter-individual variation
in trained immunity mediated by
oxidized low-density lipoprotein.
Human PBMCs isolated from 119
healthy individuals exposed for
24 h to either culture medium
alone or oxidized low-density li-
poprotein were maintained in
normal culture conditions for
5 days. On day 6, the cells were
restimulated with culture medium
or lipopolysaccharide (10 ng/mL)
for 24 h and production of TNF-α
and IL-6 was measured by
enzyme-linked immunosorbent
assay. a Ratios of cytokine pro-
duction in trained vs. non-trained
monocytes isolated from healthy
volunteers (Mean ± SEM, n =
119, *p < 0.05, **p < 0.01,
Student’s t test). b Fold changes
of cytokine levels, with green/red
corresponding to decreased/
increased cytokine production re-
spectively. c, d Impact of age (c)
and gender (d) on trained cyto-
kine responses
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Fig. 3 Genetic variation in glycolytic enzymes modifies the training
response to oxidized low-density lipoprotein. a Single-nucleotide poly-
morphisms (SNPs) in genes encoding key glycolytic enzymes PFKP and
PFKFB3 suggestively associated (p < 9.99 × 10−3) with trained responses
to oxidized low-density lipoprotein (oxLDL) (cohort 1, n = 119). b
Specific SNPs proximal to PFKP and PFKFB3 associated with TNF-α
and IL-6 production respectively in cells trained with oxLDL. c SNPs in
genes encoding key glycolytic enzymes suggestively associated with
trained responses to oxidized low-density lipoprotein (oxLDL) (cohort
2, n = 215 for TNF-α, n = 228 for IL-6). d Specific SNPs within PFKP,
PFKFB3, and HK1 associated with differential pro-inflammatory cyto-
kine production in cells trained with oxLDL
J Mol Med (2020) 98:819–831 825
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these chromatin patterns and the metabolic reprogramming.
We replicated previous reports of H3K4me3 enrichment at
regulatory elements immediately upstream of genes encoding
TNF-α and IL-6 induced by oxLDL training [4]. Inhibition of
glycolysis with 2-DG precluded the enrichment of
H3K4me3 at these gene promoters (Fig. 4e and f).
Furthermore, we observed similar enrichment of
H3K4me3 at the promoters of PFKFB3 and HK2 induced
by training with oxLDL, which was also attenuated when
glycolysis was inhibited by 2-DG. On the other hand, we
did not observe H3K4me3 enrichment at the PFKP promoter,
which is in line with the lack of transcriptional upregulation
following LPS exposure (Fig. 4g). Collectively, these data
highlight the necessity of glucose metabolism for the
induction of trained immunity, and the interconnectedness
with epigenetic remodeling.
High glucose concentrations exacerbate
oxLDL-induced trained immunity
Atherosclerotic cardiovascular disease (ASCVD) risk is se-
verely elevated in individuals with diabetes [20]. Moreover,
hyperglycemia is an independent risk factor for ASCVD in the
diabetic population [9, 21, 22]. We hypothesized that glucose
availability could modulate the pro-inflammatory, glycolysis-
dependent properties of trained immunity, thereby amplifying
the already heightened atherogenicity of macrophages trained
with oxLDL. In general, studies of primary monocytes and
macrophages, including investigations of trained immunity,
are conducted using 11 mM glucose in vitro [17]. We con-
firmed that human primary monocytes could be trained with
oxLDL in cell culture medium supplemented with the more
physiologically relevant glucose concentration of 5 mM, thus
demonstrating that in vitro trained immunity is not an artifact
of specific culture conditions (Fig. 5a). Next, we measured the
capacity of monocytes isolated from the same individuals to
be trained under variable glucose concentrations. Indeed, 24-h
co-incubation with 25 mM glucose exacerbated the training
effect of oxLDL on TNF-α production, compared with cells
trained in the presence of 5 mM glucose (Fig. 5a).
Furthermore, we observed that overnight incubation with a
high concentration glucose alone induced a trained phenotype
(Fig. 5a, compare open bars). While considerable variation in
the magnitude of oxLDL-induced training was observed
at 5 mM glucose, the high glucose medium augmented
the trained TNF-α production in nearly all individuals
tested (Fig. 5b).
Fig. 4 Pharmacological inhibition of glycolysis prevents trained
immunity induced by oxLDL. a, b Monocytes were incubated for 24 h
with culture medium (RPMI, open bars) or oxLDL (closed bars), alone or
in combination with the specific PFKFB3 inhibitor 3PO. Following
restimulation with LPS, TNF-α (a) and IL-6 (b) production was mea-
sured in the supernatants by enzyme-linked immunosorbent assay (mean
± SEM, n = 4 *p < 0.05, **p < 0.01, Wilcoxon signed-rank test). c, d
Monocytes were incubated for 24 h with culture medium (RPMI open
bars) or oxLDL (closed bars), with or without glycolysis inhibitor 2-DG.
At day 6, TNF-α (c) and IL-6 (d) production was measured by enzyme-
linked immunosorbent assay in supernatants after stimulation with LPS
(mean ± SEM, n = 6 *p < 0.05, **p < 0.01Wilcoxon signed-rank test). e–
g Soluble chromatin was isolated from cells incubated with RPMI or
oxLDL alone or in combination with 2-DG and immunopurified with
anti-H3K4me3 antibody. Schematic representations of the human TNF
and IL6 genes highlighting the regions (R1–5 for TNF, R1–2 for IL6) of
chromatin specifically analyzed for histone modifications are shown in
the top panel of e and f respectively. Quantitative RT-PCR was used to
measure the level of enrichment (lower panels) following co-incubation
with oxLDL and 2-DG at promoter regions proximal to genes encoding e
TNF-α and f IL-6. g H3K4me3 enrichment was also assessed at the
proximal promoters of glycolytic genes PFKFB3,HK2, andPFKP (mean
± SEM, n = 6 *p < 0.05, Wilcoxon signed-rank test)
Fig. 5 High glucose concentrations exacerbate trained immunity induced
by oxLDL. a Monocytes were incubated for 24 h with culture medium
(open bars) or oxLDL (closed bars) in culture medium supplementedwith
25 mM glucose or 5 mM glucose and 20 mM mannitol. Cells were then
washed with warm PBS and incubated in normal culture medium
supplemented with 6 mM glucose. Following 5 days in culture, the
cells were restimulated with medium alone or 10 ng/mL LPS for 24 h
and TNF-α production was measured in the supernatants by enzyme-
linked immunosorbent assay (mean ± SEM, n = 20, *p < 0.05, Student’s
t test). b TNF-α production by cells isolated from the same individual and
trained with oxLDL in medium supplemented with 5 mM glucose and
25 mM glucose (n = 20, *p < 0.05, Wilcoxon signed-rank test)
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Metformin prevents oxLDL-induced trained immunity
in vitro and in vivo
Metformin is the antihyperglycemic drug of first choice in
patients with type 2 diabetes mellitus. While the mechanism
of action is complex, metformin is known to activate AMP-
activated protein kinase and subsequently inhibit mechanistic
target of rapamycin (mTOR) [23]. In addition, metformin also
inhibits complex I of the mitochondria electron transport chain
and thereby inhibits OXPHOS. We previously demonstrated
that inhibition of the mTOR pathway by metformin counter-
acts the induction of trained immunity by β-glucan in vivo
[13, 16]. To assess whether metformin can similarly modulate
oxLDL-mediated trained immunity, we first investigated the
effects in vitro. Following restimulation with LPS, TNF-α
production was significantly reduced in cells co-incubated
with oxLDL and metformin (Fig. 6a). Next, we conducted a
study in healthy volunteers treated with metformin for 6 days.
Peripheral blood mononuclear cells were isolated before initi-
ation of treatment, during metformin treatment (6-day time
point) and after treatment (9- and 20-day time points), and
trained ex vivo for 24 h with oxLDL (Fig. 6b). We observed
that oxLDL-induced trained immunity was abolished by
metformin in vivo (6-day time point), and restored after ces-
sation of treatment (Fig. 6c).
Discussion
The ability of human innate immune cells to build a de facto
immunological memory of infectious challenges has been re-
cently described [2]. In parallel, we recently showed that ex-
posure ofmonocytes to a low concentration of oxLDL induces
a sustained pro-inflammatory and atherogenic phenotype [4].
This trained immunity phenotype can also be induced by a
Western type diet in Ldlr−/− mice and likely represents an
important novel mechanism in atherogenesis [24]. We now
provide several lines of evidence demonstrating that the de-
velopment of trained immunity by oxLDL is critically depen-
dent on changes in intracellular metabolism, in particular gly-
colysis and oxidative phosphorylation. These findings im-
prove our understanding of the mechanism of trained immu-
nity induced by oxLDL and point toward novel targets for
pharmacotherapy.
The importance of changes in cellular glucose metabolism
was previously indicated for the development of
Fig. 6 Metformin prevents
oxLDL-induced trained immunity
in vitro and in vivo. a, b TNF-α
production by human monocytes
trained in vitro with oxidized low-
density lipoprotein (oxLDL,
closed bars) and restimulated with
lipopolysaccharide (10 ng/mL)
(a) in the presence or absence of
10 μM metformin (mean ± SEM,
n = 5 *p < 0.05, Wilcoxon signed-
rank test). c Graphical outline of
the in vivo metformin study.
Peripheral blood mononuclear
cells were isolated from healthy
volunteers before initiation of
treatment, during treatment, and
after treatment with metformin,
and exposed for 24 h to oxLDL
(10 μg/mL). d At day 6 of the
ex vivo training protocol, the cells
were restimulated with lipopoly-
saccharide and Pam3Cys and cy-
tokines were measured by
enzyme-linked immunosorbent
assay (mean ± SEM, n = 11,
*p < 0.05, **p < 0.01 compared
with RPMI control, Wilcoxon
signed-rank test)
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atherosclerosis [12]. In atherosclerotic plaque macrophages,
glycolytic metabolism is elevated [25]. In accordance with
our findings, mRNA expression of glycolytic rate-limiting
enzymes hexokinase 2 (HK2) and PFKFB3 is significantly
elevated in monocytes isolated from patients with symptom-
atic atherosclerosis [10]. Furthermore, attenuation of glycoly-
sis by silencing or inhibiting Pfkfb3 in high fat-fed ApoE−/−
mice correlated with a significant reduction in aortic tissue
levels of TNF-α and CCL2 [26]. This association is further
underscored by recent reports describing that glucose over-
utilization drives the excessive production of IL-6 and IL-1β
by monocytes and macrophages derived from patients with
coronary artery disease, by a process that is dependent on
redox-sensitive STAT3 signaling [27].
Here, we describe the critical importance of glucose me-
tabolism for monocytes to build an immunological memory
after oxLDL stimulation, underwriting their capacity to mount
a subsequently heightened response to TLR stimulation. Our
results closely mirror aspects of the metabolic reprogramming
induced by microbial stimulators of trained immunity. Indeed,
genetic variation in HK2 and PFKP modulates the induction
of trained immunity by BCG [15]. Furthermore, we demon-
strate that this activation of glycolysis is at least partly depen-
dent on the epigenetic modification of promoters of genes that
regulate glycolytic metabolism.
By supplying the energy required for different states of acti-
vation, metabolic pathways distinguish and support the spec-
trum of macrophage phenotypes. Though energetically less ef-
ficient than OXPHOS, a potential explanation for the depen-
dency on glycolysis is that this metabolic pathway can be rap-
idly amplified to meet the ATP requirements of trained cells,
and that the ATP producing capacity of the TCA cycle is limited
by anaplerotic repurposing of TCA cycle intermediates, as de-
scribed for β-glucan-induced training [13]. Indeed, trained
monocytes consume significantly more glucose than naive cells
under resting conditions [15, 16]. On the other hand, the meta-
bolic profiles induced by these stimuli are distinguishable by
OXPHOS: OXPHOS is increased in cells trained with BCG
and oxLDL, whereas cells trained with β-glucan exhibit a
marked reduction in oxygen consumption while increasing
their glucose utilization [16]. Currently, the underlying mecha-
nisms and broader implications of these differences are unclear.
Our study is limited by our focus on the role of glycolysis in
oxLDL-mediated metabolic regulation in trained immunity.
While this is clearly a crucial pathway for the induction of
trained immunity by other stimuli such as BCG [15] and β-
glucan [16], inhibition of the electronic transport chain by met-
formin also leads to downregulation of oxLDL-induced trained
immunity, suggesting a role for OXPHOS in the establishment
of the maladaptive phenotype by oxLDL.
Our observation that pharmacological blockade of glycol-
ysis prevents oxLDL-mediated trained immunity suggests that
this pathway represents a potential therapeutic target to
prevent ASCVD. Similar to findings reported for β-glucan-
induced trained immunity [16], inhibiting the glycolytic activ-
ity of cells trained with oxLDL precluded the enrichment of
H3K4me3 at pro-inflammatory cytokine promoters.
Combined with our observations of H3K4me3 enrichment at
the promoters of transcriptionally activated glycolytic genes,
these findings further highlight the intimate bi-directional re-
lationship between metabolic and epigenetic programming
and the trained phenotype. While we demonstrate here the
impact of oxLDL training on H3K4me3 at discrete promoters
of immune genes and essential glycolytic genes, further study
is needed to examine this histone modification epigenome-
wide. In addition, investigation of other histone modifications
such as H3K4 monomethylation, a characteristic feature of
enhancers previously associated with trained immunity [28],
could provide important mechanistic insight into the pheno-
type induced by oxLDL.
Accelerated atherosclerosis is the principal cause of mor-
tality in patients with diabetes [20]. Our observation that gly-
colysis is upregulated in oxLDL-trained monocytes raises the
intriguing possibility that increased glucose availability pro-
vides substrate for glycolytic metabolism, thereby amplifying
the already heightened atherogenicity of trained macrophages
[7]. In accordancewith this hypothesis, GLUT1-mediated glu-
cose metabolism was recently reported to drive a pro-
inflammatory macrophage phenotype supported by glycolytic
metabolism [29]. Our investigation of trained immunity under
variable glucose concentrations demonstrates that high glu-
cose exacerbates cytokine production in oxLDL-induced
trained cells even further. In addition, we observed that glu-
cose by itself can induce a trained phenotype in human pri-
mary macrophages. Previous studies have described an epige-
netic memory of hyperglycemia in myeloid cells [30]; how-
ever, this phenomenon is yet to be explored thoroughly in the
context of pro-inflammatory cytokine production. Therefore,
our findings have broader implications for monocyte/
macrophage function and phenotype in the disturbed metabol-
ic environment of diabetes, which could translate to an in-
creased risk for ASCVD [9]. Furthermore, we showed that
metformin prevents oxLDL-induced trained immunity, sug-
gesting that metformin could prevent atherosclerosis in pa-
tients for whom trained immunity is part of the pathophysio-
logical process. Indeed, it has been speculated that metformin
limits atherosclerosis by mechanisms independent of blood
glucose lowering since it reduces cardiovascular disease com-
pared with other antihyperglycemic drugs despite similar gly-
cemic control. Inhibition of trained immunitymight contribute
to this beneficial cardiovascular effect of metformin.
In conclusion, we show distinguishable changes in the glu-
cose metabolism of human primary monocytes mediated by
brief exposure to a low concentration of oxLDL. Our cohort
analyses revealed the importance of genetic variation in gly-
colytic regulators for the induction of trained immunity, and
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by targeting this metabolic pathway, we demonstrate the
critical importance of glycolysis for the induction of a
pro-inflammatory monocyte phenotype in oxLDL-trained
macrophages. We propose that strategies interfering with
glucose utilization specifically in the context of trained
immunity may represent novel approaches to the treat-
ment of vascular inflammation and atherosclerosis.
However, further studies are necessary to strengthen
the connection between our findings and human disease.
For example, the use of recombinant high-density lipo-
protein nanoparticles to deliver statins directly to mac-
rophages in atherosclerotic lesions [31] could be simi-
larly deployed to target specific aspects of glycolytic
metabolism or epigenetic pathways implicated in trained
immunity [3]. Further studies should expand on the role
of epigenetic modifications in regulating key genes in
atherogenic models of trained immunity, emphasizing
the crucial connections between metabolites and
chromatin-modifying reactions [3, 13, 32].
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